Duke Kunshan University Establishes Innovation Lab for China Vaccine Delivery Research

16 December 2021

Duke Kunshan University’s Global Health Research Center received a grant from the Bill & Melinda Gates Foundation to establish the Innovation Lab for Vaccine Delivery Research. Launched in December 2021, the laboratory, led by Professor Shenglan Tang, aims to generate new scientific evidence to inform policy-making to strengthen and improve China’s National Immunization Program (NIP), and provide technical assistance for pilot research and rollout of vaccines recommended by the World Health Organization (WHO). The lab has established extensive partnerships with Duke Global Health Institute and other institutions, including the Chinese Center for Disease Control and Prevention (China CDC), leading universities, research centers and industry.

Since its establishment, the laboratory has started to commission a number of small studies and policy reviews on new vaccine introduction and innovative immunization service delivery and financing; provide technical assistance to the Gates Foundation grantees in undertaking related research; disseminate new research findings and knowledge for development of related disciplines; and support training and capacity-building of professionals in this field.

The laboratory has collaborated with several universities and disease prevention and control institutions in China to fund vaccine-related studies, including a project led by Peking University to assess the disease burden of childhood streptococcus pneumoniae infection in Qinghai and Hainan provinces; study led by Sichuan University to assess the effectiveness of two current vaccine payment strategies in increasing HPV vaccination rates in Chengdu; project led by Beijing Center of Disease Prevention and Control to conduct a cross-sectional study of the prevalence of nasopharyngeal pneumococcal infection in healthy children under 6 years of age in Hainan province; study led by Zhejiang University to identify demand-side factors affecting the efficiency of childhood vaccination; and project led by Shenzhen Maternity & Child Healthcare Hospital to survey intentions to receive the cervical cancer vaccine planned to rollout in Shenzhen. These projects will be carried out over the coming 1-2 years, aiming to provide scientific evidence for the implementation of vaccine introductions and improvement of immunization programs across China.